市场调查报告书
商品编码
1396578
智慧吸入器市场 - 按产品、疾病适应症、配销通路- 全球预测,2023-2032 年Smart Inhalers Market - By Product, By Disease Indication, By Distribution Channel - Global Forecast, 2023-2032 |
由于全球呼吸系统疾病盛行率激增,智慧吸入器市场规模预计从 2023 年到 2032 年将以 8.6% 的复合CAGR扩大。
随着气喘和慢性阻塞性肺病 (COPD) 等疾病负担的不断加重,对先进呼吸护理解决方案(尤其是智慧吸入器)的需求正在激增。根据 2023 年 CDC 报告,慢性阻塞性肺病每年影响美国超过 1,600 万人。智慧吸入器透过剂量提醒和即时监控等功能提高药物依从性。此外,随着医疗保健领域拥抱远距医疗和远距患者监控,市场必将获得巨大的发展动力。
该行业分为产品、疾病适应症、配销通路和地区。
从产品来看,基于MDI 的智慧吸入器市场在2022 年获得了巨大的吸引力,预计到2032 年将实现9.1% 的增长率。基于MDI 的智慧吸入器将技术与传统吸入设备相结合,以增强药物依从性和监测。这些智慧吸入器还有助于为患者提供即时资料追踪、剂量提醒和个人化见解,以改善整体呼吸管理。 MDI 设备的使用者友善性与数位连接的优势相结合也将促进该细分市场的成长。
就配销通路而言,由于呼吸系统疾病负担日益加重以及人们对便捷医疗解决方案的日益青睐,电子商务领域的智能吸入器市场预计将在 2023 年至 2032 年间以 10% 的CAGR产生可观的收入。比较产品、阅读用户评论和线上获取资讯的便利性正在增强消费者的决策能力。此外,数位健康和远距医疗的上升趋势可能会推动该领域的扩张。
从地区来看,2023 年至 2032 年欧洲智慧吸入器产业的复合CAGR预计将达到 8.9%。该地区先进的医疗基础设施以及呼吸道疾病的高发病率正在促进创新呼吸护理解决方案的采用。此外,製药公司和科技公司持续投资开发与数位技术相结合的智慧吸入器,以有效管理气喘和慢性阻塞性肺病,以及增加患者参与计划,将加速区域产业的扩张。例如,2023 年 7 月,梯瓦製药 (Teva) 在英国推出了新型数位化吸入器,用于治疗气喘和慢性阻塞性肺病 (COPD) 患者。
Smart Inhalers Market size is set to expand at 8.6% CAGR from 2023-2032 attributed to the surging prevalence of respiratory conditions globally.
With the rising burden of conditions like asthma and chronic obstructive pulmonary disease (COPD), the demand for advanced respiratory care solutions, particularly smart inhalers, is surging. According to the 2023 CDC reports, COPD affects over 16 million individuals in the U.S. every year. Smart inhalers offer improved medication adherence through features, such as dosage reminders and real-time monitoring. Furthermore, with the healthcare landscape embracing telemedicine and remote patient monitoring, the market is set to gain significant momentum.
The industry is segmented into product, disease indication, distribution channel, and region.
Based on product, the MDI-based smart inhalers market gained significant traction in 2022 and is anticipated to witness 9.1% growth rate through 2032. MDI-based smart inhalers integrate technology with traditional inhalation devices for enhancing medication adherence and monitoring. These smart inhalers also facilitate real-time data tracking, dosage reminders, and personalized insights for patients for improving the overall respiratory management. The user-friendly nature of MDI devices combined with the benefits of digital connectivity will also contribute the segment growth.
In terms of distribution channel, the smart inhalers market from the e-commerce segment is projected to generate considerable revenue at 10% CAGR between 2023 and 2032 attributed to the rising burden of respiratory conditions and the increasing preference for convenient healthcare solutions. The ease of comparing products, reading user reviews, and obtaining information online is leading to enhanced consumer decision-making. Moreover, the rising trend of digital health and telemedicine is likely to fuel the segment expansion.
Regionally, the Europe smart inhalers industry is set to witness robust growth at 8.9% CAGR from 2023-2032. The presence of sophisticated healthcare infrastructure coupled with a high prevalence of respiratory diseases in the region is fostering the adoption of innovative respiratory care solutions. Additionally, the ongoing investments by pharmaceutical companies and technology firms for the development of smart inhalers integrated with digital technologies for effective management of asthma and COPD along with increased patient engagement initiatives will accelerate the regional industry expansion. For instance, in July 2023, Teva unveiled its new digitally enabled inhaler in the U.K. for patients suffering from asthma and COPD.